ACP3

Across TCGA pan-cancer cohorts, ACP3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ACP3 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACP3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACP3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where ACP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	1.000	0.858	.004	41	view →
LUAD	DFS	Quartile	All	0.800	0.998	.003	12	view →
GBM	DFS	Tertile	All	0.689	0.910	.002	4	view →
HNSC	DFS	Tertile	III,IV	0.743	0.504	.041	3	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
UCEC	OS	Quartile	All	1.000	0.854	.037	2	view →
LSCC	DFS	Median	II,III,IV	0.818	0.568	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ACP3–CCRCC (OS)

Open the CCRCC breakdown →